PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23160140-1 2013 Cyclosporin A (CsA), tacrolimus and rapamycin are immunosuppressive agents (IAs) associated with insulin resistance and dyslipidemia, although their molecular effects on lipid metabolism in adipose tissue are unknown. Cyclosporine 15-18 insulin Homo sapiens 97-104 23965946-8 2013 CONCLUSION: Insulin resistance on glucose load (log post-glucose-IR), plasma high-density lipoprotein cholesterol levels, and smoking were significantly associated with CSA (r=0.225, P=0.004; r=-0.313, P<0.001; and r=0.258, P=0.001, respectively). Cyclosporine 169-172 insulin Homo sapiens 12-19 23853103-2 2013 The trials from decades ago using Cyclosporine A in significantly lower dosages than used for organ transplantation and in similar dosages that have increased T regulatory cell populations in conditions such as atopic dermatitis, demonstrated very high initial insulin-free remission rates when administered immediately after diagnosis. Cyclosporine 34-48 insulin Homo sapiens 261-268 23853103-3 2013 Over time, all newly diagnosed type 1 patients given Cyclosporine A required insulin. Cyclosporine 53-67 insulin Homo sapiens 77-84 23432070-2 2013 Because cyclosporine is less diabetogenic than tacrolimus is, cyclosporine may be preferred in patients with pre-existing diabetes mellitus type 2, to prevent insulin treatment after a transplant. Cyclosporine 62-74 insulin Homo sapiens 159-166 23432070-5 2013 RESULTS: Of the 16 patients treated with cyclosporine, only 4 remained free of insulin treatment after a follow-up of least 1 year, compared with 2 of 12 patients who were treated with tacrolimus (25% vs 17%; P = .67). Cyclosporine 41-53 insulin Homo sapiens 79-86 23432070-8 2013 CONCLUSIONS: Cyclosporine cannot be preferred over tacrolimus to minimize either the chance of requiring insulin treatment posttransplant or the dosage of insulin in patients with pre-existing diabetes mellitus type 2. Cyclosporine 13-25 insulin Homo sapiens 105-112 23160140-7 2013 These findings suggest that CsA, tacrolimus and rapamycin enhance lipolysis, inhibit lipid storage and expression of lipogenic genes in adipose tissue, which may contribute to the development of dyslipidemia and insulin resistance associated with immunosuppressive therapy. Cyclosporine 28-31 insulin Homo sapiens 212-219 18709005-0 2008 Clinical importance of insulin resistance after renal transplantation in patients on triple immunosuppressive therapy with cyclosporine, corticosteroids and mycophenolate mofetil. Cyclosporine 123-135 insulin Homo sapiens 23-30 23018257-0 2012 Influence of conversion from cyclosporine A to tacrolimus on insulin sensitivity assessed by euglicaemic hyperinsulinemic clamp technique in patients after kidney transplantation. Cyclosporine 29-43 insulin Homo sapiens 61-68 21988494-4 2012 WHAT THIS STUDY ADDS: This is the first trial to investigate beta cell function and insulin sensitivity using gold standard methodology in healthy human volunteers treated with clinically relevant doses of ciclosporin and tacrolimus. Cyclosporine 206-217 insulin Homo sapiens 84-91 21988494-17 2012 CsA, and to a lesser degree Tac infusions, in healthy volunteers include increased insulin sensitivity, without any effect on first phase or pulsatile insulin secretion. Cyclosporine 0-3 insulin Homo sapiens 83-90 21465949-6 2011 Substitution of tacrolimus with cyclosporine obviated the need for insulin or oral hypoglycaemics. Cyclosporine 32-44 insulin Homo sapiens 67-74 23003106-6 2012 RESULTS: Cyclosporine and tacrolimus decreased insulin sensitivity by 22% (P = 0.02) and 13% (P = 0.048), respectively. Cyclosporine 9-21 insulin Homo sapiens 47-54 23003106-8 2012 CONCLUSION: In conclusion, 8-10 days of treatment with cyclosporine and tacrolimus impairs insulin sensitivity to a similar degree in haemodialysis patients, while acute insulin responses and pulsatile insulin secretion remain unaffected. Cyclosporine 55-67 insulin Homo sapiens 91-98 22897149-0 2012 Insulin independence after conversion from tacrolimus to cyclosporine in islet transplantation. Cyclosporine 57-69 insulin Homo sapiens 0-7 20351753-5 2011 A reduced number of insulin granule fusion events accompanied the decrease in insulin secretion in CsA-treated cells expressing ZnT-8 R325; however, ZnT-8 W325-expressing cells exhibited resistance to the dampening of insulin granule fusion by CsA, and transported zinc ions into secretory vesicles more efficiently. Cyclosporine 99-102 insulin Homo sapiens 20-27 20351753-5 2011 A reduced number of insulin granule fusion events accompanied the decrease in insulin secretion in CsA-treated cells expressing ZnT-8 R325; however, ZnT-8 W325-expressing cells exhibited resistance to the dampening of insulin granule fusion by CsA, and transported zinc ions into secretory vesicles more efficiently. Cyclosporine 99-102 insulin Homo sapiens 78-85 20351753-5 2011 A reduced number of insulin granule fusion events accompanied the decrease in insulin secretion in CsA-treated cells expressing ZnT-8 R325; however, ZnT-8 W325-expressing cells exhibited resistance to the dampening of insulin granule fusion by CsA, and transported zinc ions into secretory vesicles more efficiently. Cyclosporine 244-247 insulin Homo sapiens 20-27 20440520-13 2010 Low-dose cyclo and mtx treatment of subjects with new onset T1D can safely induce remission of disease and decrease the amount of required insulin. Cyclosporine 9-14 insulin Homo sapiens 139-146 18709005-15 2008 Higher CsA trough levels are assotiated with higher Insulin values and indexes of IR. Cyclosporine 7-10 insulin Homo sapiens 52-59 17299003-0 2007 The impact of short-term ciclosporin A treatment on insulin secretion and insulin sensitivity in man. Cyclosporine 25-38 insulin Homo sapiens 52-59 16549165-1 2006 BACKGROUND: Insulin resistance, a frequent prediabetic metabolic complication after renal transplantation, is generally linked to immunosuppressive drugs including corticosteroids, cyclosporine (CsA) or tacrolimus, as well as to age, cadaveric donors and ethnic factors. Cyclosporine 195-198 insulin Homo sapiens 12-19 16549165-1 2006 BACKGROUND: Insulin resistance, a frequent prediabetic metabolic complication after renal transplantation, is generally linked to immunosuppressive drugs including corticosteroids, cyclosporine (CsA) or tacrolimus, as well as to age, cadaveric donors and ethnic factors. Cyclosporine 181-193 insulin Homo sapiens 12-19 15326467-13 2004 Fasting insulin was negatively correlated with CSA output on levels of adjustment. Cyclosporine 47-50 insulin Homo sapiens 8-15 15848603-7 2005 After conversion to CSA, among the 3 patients started on insulin, 1 has come completely off antidiabetic medications, whereas 1 required decreased doses of insulin, and the third has been converted to oral medications. Cyclosporine 20-23 insulin Homo sapiens 57-64 15686683-0 2004 Impact of kidney transplantation on glycemic control and cardiovascular risk factors in insulin-treated diabetic patients receiving cyclosporine: a longitudinal study. Cyclosporine 132-144 insulin Homo sapiens 88-95 15686683-2 2004 In 10 selected insulin-treated diabetic patients with normally functioning kidney transplants, receiving cyclosporine for immunosuppression, we evaluated the fasting blood glucose, HbA1c, lipid levels, blood pressure, and insulin-requirement from 1 year before to 1 year after KTP. Cyclosporine 105-117 insulin Homo sapiens 15-22 15575024-9 2004 A comparison of the effects of tacrolimus and ciclosporin on glucose metabolism revealed reduced insulin release with tacrolimus at week 3 post-transplant, but for the remainder of the 3 year follow-up there were no significant differences between the two treatment arms. Cyclosporine 46-57 insulin Homo sapiens 97-104 12761338-0 2003 Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice. Cyclosporine 78-91 insulin Homo sapiens 20-27 12761338-8 2003 After stimulation with glucose, human insulin promoter-mediated gene expression was inhibited in normal, mature islet cells by both tacrolimus and cyclosporin A to a large extent (approximately 70%) and with high potency at concentrations that are known to inhibit calcineurin phosphatase activity (IC50 values of 1 and 35 nM, respectively). Cyclosporine 147-160 insulin Homo sapiens 38-45 12761338-10 2003 The high potency of cyclosporin A and tacrolimus in normal islets suggests that inhibition of insulin gene transcription by cyclosporin A and tacrolimus is clinically important and is one mechanism of the diabetogenic effect of these immunosuppressive drugs. Cyclosporine 20-33 insulin Homo sapiens 94-101 12761338-10 2003 The high potency of cyclosporin A and tacrolimus in normal islets suggests that inhibition of insulin gene transcription by cyclosporin A and tacrolimus is clinically important and is one mechanism of the diabetogenic effect of these immunosuppressive drugs. Cyclosporine 124-137 insulin Homo sapiens 94-101 12087018-0 2002 IA-2 antibody-negative status predicts remission and recovery of C-peptide levels in type 1 diabetic patients treated with cyclosporin. Cyclosporine 123-134 insulin Homo sapiens 65-74 12848377-0 2003 Influence of long term cyclosporine therapy on insulin and its precursors secretion in patients after heart transplantation. Cyclosporine 23-35 insulin Homo sapiens 47-54 12848377-7 2003 We observed a statistically significant negative correlation between CyA concentration and insulin in both groups, a statistically significant negative correlation between CyA concentration and proinsulin, C-peptide blood level in group 1 and statistically significant positive correlation between CyA and glucose blood level in both groups. Cyclosporine 69-72 insulin Homo sapiens 91-98 12848377-7 2003 We observed a statistically significant negative correlation between CyA concentration and insulin in both groups, a statistically significant negative correlation between CyA concentration and proinsulin, C-peptide blood level in group 1 and statistically significant positive correlation between CyA and glucose blood level in both groups. Cyclosporine 172-175 insulin Homo sapiens 194-204 12848377-7 2003 We observed a statistically significant negative correlation between CyA concentration and insulin in both groups, a statistically significant negative correlation between CyA concentration and proinsulin, C-peptide blood level in group 1 and statistically significant positive correlation between CyA and glucose blood level in both groups. Cyclosporine 172-175 insulin Homo sapiens 194-204 12486498-7 2002 Insulin gene expression was significantly reduced only in islets exposed to CsA. Cyclosporine 76-79 insulin Homo sapiens 0-7 12486498-8 2002 FK506 was, among those tested, the immunosuppressive drug that most profoundly altered the normal insulin secretory pattern of human beta-cells, whereas CsA was the only inhibiting insulin gene expression. Cyclosporine 153-156 insulin Homo sapiens 181-188 12644894-0 2003 Regulation of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus at concentrations that inhibit calcineurin activity and involving the transcription factor CREB. Cyclosporine 78-91 insulin Homo sapiens 20-27 12644894-5 2003 However, after stimulation by the major second messengers in the regulation of the insulin gene, cAMP and depolarization-induced calcium influx, both tacrolimus and cyclosporin A inhibited human insulin gene transcription in a concentration-dependent manner with IC(50) values of 1 nM and 30 nM, respectively. Cyclosporine 165-178 insulin Homo sapiens 83-90 12644894-5 2003 However, after stimulation by the major second messengers in the regulation of the insulin gene, cAMP and depolarization-induced calcium influx, both tacrolimus and cyclosporin A inhibited human insulin gene transcription in a concentration-dependent manner with IC(50) values of 1 nM and 30 nM, respectively. Cyclosporine 165-178 insulin Homo sapiens 195-202 12644894-7 2003 These data demonstrate for the first time that cAMP- and calcium-induced activity of the human insulin gene is mediated by CREB and blocked by both tacrolimus and cyclosporin A at concentrations that inhibit calcineurin phosphatase activity. Cyclosporine 163-176 insulin Homo sapiens 95-102 12644894-8 2003 Since also the immunosuppressive effects of cyclosporin A and tacrolimus are thought to be secondary to inhibition of calcineurin, the present study suggests that inhibition of human insulin gene transcription by the immunosuppressants is clinically important and may contribute to their diabetogenic effect. Cyclosporine 44-57 insulin Homo sapiens 183-190 12087018-8 2002 Cyclosporin caused significant reduction in insulin requirements and significant increases in C-peptide secretion mainly in patients negative for IA-2 antibodies. Cyclosporine 0-11 insulin Homo sapiens 94-103 7973537-0 1994 [The effect of long-term cyclosporin and prednisone therapy on insulin secretory reserve]. Cyclosporine 25-36 insulin Homo sapiens 63-70 11752040-10 2002 The only significant difference between patients who received tacrolimus and those who received cyclosporine was in pancreatic secretion capacity at week 3 after transplantation, when the increment of C-peptide secretion was 57% lower and the increment of insulin secretion was 48% lower for patients receiving tacrolimus. Cyclosporine 96-108 insulin Homo sapiens 201-210 11390035-9 2001 Additionally, alteration of insulin release from PIC cultured with PBMC or plastic-adherent cells was abolished dose-dependently (p < 0.0001 and p < 0.04, respectively) by gadolinium chloride (which inhibits macrophages), but not modified by cyclosporin A or mycophenolate mofetil which did not alter insulin release from PIC but blocked the proliferation of PBMC against PIC. Cyclosporine 248-261 insulin Homo sapiens 28-35 9702422-0 1998 Successful treatment with plasmapheresis, cyclophosphamide, and cyclosporin A in type B syndrome of insulin resistance. Cyclosporine 64-77 insulin Homo sapiens 100-107 9558194-2 1998 Cyclosporine therapy induced a remission of receptor antibody mediated insulin resistance and controlled clinical manifestations of her systemic lupus erythematosus and dermatomyositis, but had no effect on the sclerodermatous features of her illness. Cyclosporine 0-12 insulin Homo sapiens 71-78 9113492-8 1997 Cyclosporin and tacrolimus cause post-transplant diabetes mellitus by a number of mechanisms, including decreased insulin secretion, increased insulin resistance or a direct toxic effect on the beta cell. Cyclosporine 0-11 insulin Homo sapiens 114-121 9116920-0 1997 Development of insulin resistance and elevated blood pressure during therapy with cyclosporine A. Cyclosporine 82-96 insulin Homo sapiens 15-22 9115576-1 1996 We conducted a pilot study of immunosuppression with low dose cyclosporine in first degree relatives of diabetic patients with immunologic and metabolic criteria for preclinical diabetes: islet cell antibodies (ICA) > or = 20 Juvenile Diabetes Foundation (JDF) units, first phase insulin response < 10th percentile and impaired glucose tolerance. Cyclosporine 62-74 insulin Homo sapiens 283-290 7781843-3 1995 Cyclosporin (CyA) and nicotinamide (NA), alone or in combination, can preserve this function, as indicated by the parameters of metabolic control (insulin dose, HbA1C). Cyclosporine 0-11 insulin Homo sapiens 147-154 7781843-3 1995 Cyclosporin (CyA) and nicotinamide (NA), alone or in combination, can preserve this function, as indicated by the parameters of metabolic control (insulin dose, HbA1C). Cyclosporine 13-16 insulin Homo sapiens 147-154 11707743-12 2001 A decrease of insulin release by PBMCs was reproduced with plastic-adherent cells and was abolished by depletion of MHC class II+ cells or by addition of 100 microg/ml gadolinium (which inhibits macrophages), but not by cyclosporine. Cyclosporine 220-232 insulin Homo sapiens 14-21 11562451-2 2001 In the present article we show that 2 to 5 microM CsA diminishes glucose-induced insulin secretion of isolated mouse pancreatic islets in vitro by inhibiting glucose-stimulated oscillations of the cytoplasmic free-Ca(2+) concentration [Ca(2+)](c). Cyclosporine 50-53 insulin Homo sapiens 81-88 10841236-9 2000 CONCLUSIONS: Vitamin C improves both endothelial function and insulin sensitivity in patients with CSA. Cyclosporine 99-102 insulin Homo sapiens 62-69 10841236-10 2000 Thus, reactive oxygen species and/or decreased nitric oxide bioactivity may play an important role in the genesis of both endothelial dysfunction and insulin resistance in patients with CSA. Cyclosporine 186-189 insulin Homo sapiens 150-157 10459544-7 1999 RESULTS: On light microscopy cytoplasmic swelling, vacuolization, apoptosis, and abnormal immunostaining for insulin were seen in biopsies from patients receiving either FK or CSA. Cyclosporine 176-179 insulin Homo sapiens 109-116 9702422-14 1998 DISCUSSION: Severe type B insulin resistance may respond favorably to treatment with plasmapheresis and cyclophosphamide followed by cyclosporin A in combination with azathioprin. Cyclosporine 133-146 insulin Homo sapiens 26-33 9493129-5 1998 These effects of insulin were completely blocked by cyclosporin-A, an inhibitor of protein phosphatase type 2B (PP2B) which dephosphorylates phospho-tyrosine in addition to phosphoserine/threonine, but not by okadaic acid, an inhibitor of protein phosphatase type 1 and 2A. Cyclosporine 52-65 insulin Homo sapiens 17-24 8685947-6 1996 Insulin output, stimulated by oral glucose tolerance tests and assessed by the ratio of AUC insulin to AUC glucose, fell gradually after transplantation and was decreased by an elevated serum calcium level and high cyclosporine dose. Cyclosporine 215-227 insulin Homo sapiens 0-7 8685947-7 1996 The ratio of fasting insulin to glucose, which acts as a marker of peripheral insulin resistance, fell with time after transplantation and was increased by greater body weight, higher prednisolone dose, and lower cyclosporine dose. Cyclosporine 213-225 insulin Homo sapiens 21-28 8685947-7 1996 The ratio of fasting insulin to glucose, which acts as a marker of peripheral insulin resistance, fell with time after transplantation and was increased by greater body weight, higher prednisolone dose, and lower cyclosporine dose. Cyclosporine 213-225 insulin Homo sapiens 78-85 8685947-8 1996 The inhibitory effect of cyclosporine on both fasting and postprandial insulin output was, however, minor when quantified by multivariate analysis. Cyclosporine 25-37 insulin Homo sapiens 71-78 8522052-8 1996 Average insulin dose remained lower by 0.2-0.4 U.kg-1.day-1 and glycated hemoglobin by approximately 1% in cyclosporin-treated patients (P < 0.02), who also had less hypoglycemia than the diabetic control subjects (P < 0.05). Cyclosporine 107-118 insulin Homo sapiens 8-15 7973537-1 1994 Insulin secretory reserve assessed by the method of glucose potentiation of arginine induced insulin secretion is decreased in non-diabetic transplant recipients using triple immunosuppressive therapy with prednisone, cyclosporine, and azathioprine. Cyclosporine 218-230 insulin Homo sapiens 0-7 7973537-3 1994 Long-term cyclosporine (ANOVA p = 0.016 compared to control subjects) but not prednisone treatment decreased insulin secretory reserve. Cyclosporine 10-22 insulin Homo sapiens 109-116 7506454-3 1993 In the present study, we have compared the effects of CsA and FK506 on glucose-stimulated insulin release from the isolated dog pancreatic islets, which have been maintained in culture for 3 days after isolation. Cyclosporine 54-57 insulin Homo sapiens 90-97 8138066-6 1994 Insulin responses were also decreased in kidney recipients (ARmax = 2,296 +/- 290%) vs. control subjects (4,691 +/- 554%, P = 0.001) and in psoriasis patients treated with cyclosporine (ARmax = 2,153 +/- 390%) vs. control subjects (3,962 +/- 88%, P = 0.011), but not as extreme as that seen in pancreas recipients. Cyclosporine 172-184 insulin Homo sapiens 0-7 7590419-8 1994 The analysis of the residual beta cell secretory capacity has shown that C-peptide levels (taken as a marker for insulin secretion) were slightly higher in patients with the spontaneous remission than in those with the cyclosporin-induced remission both in basal conditions and after stimulation with 1 mg of glucagon. Cyclosporine 219-230 insulin Homo sapiens 73-82 7590419-9 1994 In the patients with cyclosporin A-induced remission we found an improved basal C-peptide secretion and, even more, we detected a significant improvement in beta cell response to the glucagon stimulation. Cyclosporine 21-34 insulin Homo sapiens 80-89 7590419-10 1994 The analysis of the first-phase insulin secretory response (the insulin response to rapidly injected glucose during the intravenous glucose tolerance test) which has been shown to be impaired very early during the development of diabetes, has demonstrated the lack of its recovery both in the spontaneous and in cyclosporin A-induced remissions. Cyclosporine 312-325 insulin Homo sapiens 32-39 7590419-10 1994 The analysis of the first-phase insulin secretory response (the insulin response to rapidly injected glucose during the intravenous glucose tolerance test) which has been shown to be impaired very early during the development of diabetes, has demonstrated the lack of its recovery both in the spontaneous and in cyclosporin A-induced remissions. Cyclosporine 312-325 insulin Homo sapiens 64-71 7590419-11 1994 The analysis of the molar insulin/C-peptide ratio has detected the impairments of this ratio which remains decreased both in spontaneous and cyclosporin-induced remissions. Cyclosporine 141-152 insulin Homo sapiens 26-33 7590419-11 1994 The analysis of the molar insulin/C-peptide ratio has detected the impairments of this ratio which remains decreased both in spontaneous and cyclosporin-induced remissions. Cyclosporine 141-152 insulin Homo sapiens 34-43 7506454-6 1993 CsA (100 nM), which is a therapeutically relevant concentration, significantly suppressed both the first and second phases of glucose-stimulated insulin release compared with 100 nM FK506. Cyclosporine 0-3 insulin Homo sapiens 145-152 1773683-6 1991 After an average of 71 days of insulin therapy, there was complete remission of PTDM in 5 of 6 diabetic patients, with a corresponding decrease in CsA level. Cyclosporine 147-150 insulin Homo sapiens 31-38 8359107-9 1993 CONCLUSIONS: In this patient, an early start of cyclosporin therapy probably contributed to the maintenance of endogenous insulin secretion, and insulin sensitivity was high because of physical training. Cyclosporine 48-59 insulin Homo sapiens 122-129 8325202-0 1993 Hypersensitivity to insulin during remissions in cyclosporin-treated IDDM patients. Cyclosporine 49-60 insulin Homo sapiens 20-27 8325202-8 1993 CONCLUSIONS: Cyclosporin A-associated remissions represent an original situation that associates euglycemia with the persistence of low endogenous insulin secretion. Cyclosporine 13-26 insulin Homo sapiens 147-154 8325202-9 1993 Cyclosporin A by itself had no influence on sensitivity to insulin, but allowed the reappearance of some insulin secretory capacity that contributed, with the improvement of insulin sensitivity, to the development of the diabetes honeymoon. Cyclosporine 0-13 insulin Homo sapiens 105-112 8325202-9 1993 Cyclosporin A by itself had no influence on sensitivity to insulin, but allowed the reappearance of some insulin secretory capacity that contributed, with the improvement of insulin sensitivity, to the development of the diabetes honeymoon. Cyclosporine 0-13 insulin Homo sapiens 105-112 7678356-3 1993 It has been shown previously, for example, that cyclosporine may inhibit insulin release from islet tumor cells and rat islets. Cyclosporine 48-60 insulin Homo sapiens 73-80 7678356-5 1993 L-683,590 and cyclosporine inhibited insulin release by beta TC3 cells by about 50% and 80%, respectively, at doses that inhibit lymphokine production by T cells. Cyclosporine 14-26 insulin Homo sapiens 37-44 7678356-9 1993 Both drugs caused reduced levels of insulin mRNA (by 56 +/- 8.1% and 66 +/- 16% in the presence of L-683,590 and cyclosporine, respectively), accounting for reduced rates of insulin biosynthesis that were also seen. Cyclosporine 113-125 insulin Homo sapiens 36-43 7678356-9 1993 Both drugs caused reduced levels of insulin mRNA (by 56 +/- 8.1% and 66 +/- 16% in the presence of L-683,590 and cyclosporine, respectively), accounting for reduced rates of insulin biosynthesis that were also seen. Cyclosporine 113-125 insulin Homo sapiens 174-181 7678356-10 1993 Our studies indicate that: (1) both cyclosporine and L-683,590 inhibit insulin release by beta TC3 cells and cultured rat islets after 48 hr (cyclosporine is a more potent inhibitor); (2) neither drug inhibits the release of insulin during the first 4 hr following a glucose stimulus; and (3) their mechanisms of action appear to be similar--both drugs cause reduced levels of insulin mRNA. Cyclosporine 36-48 insulin Homo sapiens 71-78 7678356-10 1993 Our studies indicate that: (1) both cyclosporine and L-683,590 inhibit insulin release by beta TC3 cells and cultured rat islets after 48 hr (cyclosporine is a more potent inhibitor); (2) neither drug inhibits the release of insulin during the first 4 hr following a glucose stimulus; and (3) their mechanisms of action appear to be similar--both drugs cause reduced levels of insulin mRNA. Cyclosporine 36-48 insulin Homo sapiens 225-232 7678356-10 1993 Our studies indicate that: (1) both cyclosporine and L-683,590 inhibit insulin release by beta TC3 cells and cultured rat islets after 48 hr (cyclosporine is a more potent inhibitor); (2) neither drug inhibits the release of insulin during the first 4 hr following a glucose stimulus; and (3) their mechanisms of action appear to be similar--both drugs cause reduced levels of insulin mRNA. Cyclosporine 36-48 insulin Homo sapiens 225-232 7678356-10 1993 Our studies indicate that: (1) both cyclosporine and L-683,590 inhibit insulin release by beta TC3 cells and cultured rat islets after 48 hr (cyclosporine is a more potent inhibitor); (2) neither drug inhibits the release of insulin during the first 4 hr following a glucose stimulus; and (3) their mechanisms of action appear to be similar--both drugs cause reduced levels of insulin mRNA. Cyclosporine 142-154 insulin Homo sapiens 71-78 1397785-15 1992 Following discontinuation of cyclosporin A insulin requirements and glycated hemoglobin levels increased while glucagon-stimulated connecting peptide levels declined dramatically. Cyclosporine 29-42 insulin Homo sapiens 43-50 1897023-11 1991 The indirect evidence of insulin resistance observed in patients treated with CsA plus prednisone is ascribable to corticosteroid treatment. Cyclosporine 78-81 insulin Homo sapiens 25-32 2219367-0 1990 Influence of cyclosporine on C-peptide levels in kidney allograft recipients. Cyclosporine 13-25 insulin Homo sapiens 29-38 2210078-1 1990 Preliminary data from our group indicated that cyclosporin A induced frequent remissions of insulin dependency in a group of 40 insulin-dependent (type I) diabetic children if given at the onset of clinical manifestations of diabetes. Cyclosporine 47-60 insulin Homo sapiens 92-99 2219271-0 1990 Short-term effects of cyclosporine on secretagogue-induced insulin release by isolated islets. Cyclosporine 22-34 insulin Homo sapiens 59-66 2219271-1 1990 Brief exposure (30 min) of isolated islets to 0.5 microgram/ml cyclosporine leads to alterations in the insulin secretory response to selected stimuli. Cyclosporine 63-75 insulin Homo sapiens 104-111 2219271-2 1990 When glucose is used as the secretagogue, cyclosporine slightly stimulates insulin release at substimulatory concentrations of the hexose. Cyclosporine 42-54 insulin Homo sapiens 75-82 2219271-5 1990 Cyclosporine also inhibits by 66% the insulin secretory response to 100 nmol/L phorbol 12-myristate 13-acetate, suggesting that either cyclosporine interferes with phorbol ester action on beta cells or the action site is located beyond the protein kinase C activation. Cyclosporine 0-12 insulin Homo sapiens 38-45 2191883-11 1990 In contrast, in the CsA-treated group, the initial recovery in insulin secretory capacity was maintained over the 18-24 mo of the study. Cyclosporine 20-23 insulin Homo sapiens 63-70 2219271-6 1990 On the other hand ionomycin-stimulated insulin response is also blocked by cyclosporine, indicating that insulin release induced by transient changes in cytosolic Ca++ is also affected. Cyclosporine 75-87 insulin Homo sapiens 39-46 2219271-6 1990 On the other hand ionomycin-stimulated insulin response is also blocked by cyclosporine, indicating that insulin release induced by transient changes in cytosolic Ca++ is also affected. Cyclosporine 75-87 insulin Homo sapiens 105-112 2219271-7 1990 The evidence gathered here suggests that the inhibitory effect of cyclosporine on insulin release is apparent when glucose is used as a fuel stimulant and is reversed following removal of the stimulant. Cyclosporine 66-78 insulin Homo sapiens 82-89 2219271-8 1990 This effect is not reversed by using substances known to activate the protein kinase C or the Ca(++)-dependent branches of the stimulus-secretion coupling system in beta cells, indicating that the site of action of cyclosporine on pancreatic islets might be located in distal steps of the stimulus-secretion coupling of glucose-induced insulin release. Cyclosporine 215-227 insulin Homo sapiens 336-343 2108071-2 1990 We report the first type I diabetic patient with an established kidney transplant on basal cyclosporin immunosuppression who was able to eliminate the insulin requirement after human islet transplantation into the portal vein. Cyclosporine 91-102 insulin Homo sapiens 151-158 2190313-10 1990 Some patients with recently diagnosed insulin dependent diabetes needed no further insulin therapy as long as cyclosporine was administered. Cyclosporine 110-122 insulin Homo sapiens 38-45 2183445-0 1990 Cyclosporine inhibition of insulin secretion: effect of tolbutamide and extracellular calcium concentration. Cyclosporine 0-12 insulin Homo sapiens 27-34 2303172-0 1990 Proinsulin and C-peptide at onset and during 12 months cyclosporin treatment of type 1 (insulin-dependent) diabetes mellitus. Cyclosporine 55-66 insulin Homo sapiens 15-24 2303172-10 1990 The effect of cyclosporin on the induction of non-insulin requiring remission was unrelated to fasting and glucagon stimulated C-peptide levels at entry, whereas 64% of the cyclosporin-treated against 28% of the placebo-treated subjects (p less than 0.01) went into remission if the proinsulin/C-peptide ratio at entry was above 0.024. Cyclosporine 14-25 insulin Homo sapiens 50-57 2669194-7 1989 In experiment 1 cyclosporine did not alter IVGTTs; however, during sustained hyperglycemia, cyclosporine caused a 37% decrease in net glucose disposal (p less than 0.001) and a 39% decrease in plateau plasma insulin levels (p less than 0.05). Cyclosporine 92-104 insulin Homo sapiens 208-215 2681969-7 1989 Higher incidence of diabetes mellitus requiring insulin therapy in cyclosporin treated transplant recipients has been reported. Cyclosporine 67-78 insulin Homo sapiens 48-55 2681969-8 1989 Cyclosporin may cause toxic effects on pancreatic beta-cells resulting in inhibition of insulin secretion. Cyclosporine 0-11 insulin Homo sapiens 88-95 2669194-9 1989 Plateau insulin values in euglycemic clamp studies were lowered by 27% (p less than 0.05) after cyclosporine treatment. Cyclosporine 96-108 insulin Homo sapiens 8-15 2669194-12 1989 These experiments suggest that cyclosporine treatment results in impairment of sustained synthesis and secretion of insulin, increased insulin clearance, and unaltered insulin sensitivity. Cyclosporine 31-43 insulin Homo sapiens 116-123 2669194-12 1989 These experiments suggest that cyclosporine treatment results in impairment of sustained synthesis and secretion of insulin, increased insulin clearance, and unaltered insulin sensitivity. Cyclosporine 31-43 insulin Homo sapiens 135-142 3292324-1 1988 We report that cyclosporin A (CsA) suppresses the insulin autoantibodies that are present before insulin therapy in the sera of one-third of studied type I (insulin-dependent) diabetic children. Cyclosporine 30-33 insulin Homo sapiens 50-57 3069390-2 1988 In the Canadian open study, the rate of clinical remissions (target control of glycemia maintained with less than or equal to 0.15 U.kg-1.day-1 insulin) was unexpectedly high among 81 subjects who had been treated with cyclosporin for at least 3 mo (mean serum trough levels approximately 125 ng/ml by radioimmunoassay). Cyclosporine 219-230 insulin Homo sapiens 144-151 3292324-1 1988 We report that cyclosporin A (CsA) suppresses the insulin autoantibodies that are present before insulin therapy in the sera of one-third of studied type I (insulin-dependent) diabetic children. Cyclosporine 30-33 insulin Homo sapiens 97-104 3292324-1 1988 We report that cyclosporin A (CsA) suppresses the insulin autoantibodies that are present before insulin therapy in the sera of one-third of studied type I (insulin-dependent) diabetic children. Cyclosporine 30-33 insulin Homo sapiens 97-104 3292324-2 1988 CsA also reversibly blocks the production of antibodies after exogenous insulin injection, whereas high titers of heterologous insulin antibody are observed in all type I patients not receiving CsA. Cyclosporine 0-3 insulin Homo sapiens 72-79 3292324-2 1988 CsA also reversibly blocks the production of antibodies after exogenous insulin injection, whereas high titers of heterologous insulin antibody are observed in all type I patients not receiving CsA. Cyclosporine 194-197 insulin Homo sapiens 127-134 3316581-1 1987 Administration of cyclosporine resulted in reduced insulin requirements and improved glycemic control in patients with insulin-dependent diabetes mellitus of recent onset, but the drug was less effective in young children. Cyclosporine 18-30 insulin Homo sapiens 51-58 3290005-0 1988 Inhibition of insulin release in vitro mediated by mononuclear cells from diabetic patients treated with cyclosporin A or placebo. Cyclosporine 105-118 insulin Homo sapiens 14-21 3125434-10 1988 We conclude that early treatment with cyclosporine in children with recent-onset Type I diabetes can induce remission from insulin dependence, with half the patients not requiring insulin after a full year. Cyclosporine 38-50 insulin Homo sapiens 123-130 3041644-10 1988 A sustained euglycemic, insulin-independent state can be established in nonuremic, nonkidney diabetic recipients of pancreas transplants alone, with a beneficial effect on neuropathy, lack of an immediate benefit on advanced retinopathy, and an effect on nephropathy compounded by the influence of CsA on renal function. Cyclosporine 298-301 insulin Homo sapiens 24-31 2455447-4 1988 The incidence of diabetes mellitus (DM) requiring insulin therapy was higher in CsA-treated recipients (18/105, 17.1%) than in Az-treated recipients (23/180, 12.8%; P less than 0.05), although both the daily Pred and cumulative doses of methylprednisolone (MP) at the onset of DM were significantly smaller in the CsA group than in the Az group (26.1 +/- 2.2 mg v 41.4 +/- 3.4 mg, P less than 0.01 and 3,086 +/- 626 mg v 7,133 +/- 1,129 mg, P less than 0.01, respectively). Cyclosporine 80-83 insulin Homo sapiens 50-57 2455447-4 1988 The incidence of diabetes mellitus (DM) requiring insulin therapy was higher in CsA-treated recipients (18/105, 17.1%) than in Az-treated recipients (23/180, 12.8%; P less than 0.05), although both the daily Pred and cumulative doses of methylprednisolone (MP) at the onset of DM were significantly smaller in the CsA group than in the Az group (26.1 +/- 2.2 mg v 41.4 +/- 3.4 mg, P less than 0.01 and 3,086 +/- 626 mg v 7,133 +/- 1,129 mg, P less than 0.01, respectively). Cyclosporine 314-317 insulin Homo sapiens 50-57 2455447-7 1988 Insulin could be withdrawn within 3 months in six of eight patients who had been converted from CsA to Az. Cyclosporine 96-99 insulin Homo sapiens 0-7 3291335-0 1988 Peripheral insulin resistance and decreased insulin secretion after cyclosporine A treatment. Cyclosporine 68-82 insulin Homo sapiens 11-18 3293865-0 1988 Effect of cyclosporine on insulin binding to erythrocytes in type 1 diabetes mellitus of recent onset. Cyclosporine 10-22 insulin Homo sapiens 26-33 3293865-1 1988 The effect of cyclosporine (Cyclosporin A) on insulin binding to erythrocytes was investigated in Type 1 diabetes mellitus of recent onset. Cyclosporine 14-26 insulin Homo sapiens 46-53 3293865-1 1988 The effect of cyclosporine (Cyclosporin A) on insulin binding to erythrocytes was investigated in Type 1 diabetes mellitus of recent onset. Cyclosporine 28-41 insulin Homo sapiens 46-53 3293865-6 1988 Insulin binding at tracer concentration, reflecting the number of insulin receptors, was initially normal but tended to decrease with duration of cyclosporine administration. Cyclosporine 146-158 insulin Homo sapiens 0-7 3293865-11 1988 After discontinuation of cyclosporine for one month or more, the mean daily insulin dosage increased and plasma C-peptide decreased. Cyclosporine 25-37 insulin Homo sapiens 76-83 3293865-12 1988 Insulin binding at tracer concentration was not affected but the apparent affinity was decreased after withdrawal of cyclosporine. Cyclosporine 117-129 insulin Homo sapiens 0-7 3293865-13 1988 These results suggest that insulin action at the receptor may be affected by the administration of cyclosporine. Cyclosporine 99-111 insulin Homo sapiens 27-34 3293865-16 1988 Thus immunosuppression with cyclosporine in newly diagnosed Type 1 diabetes mellitus may have a modest adverse effect on insulin receptors; whether the benefits of cyclosporine treatment outweigh this risk is difficult to assess. Cyclosporine 28-40 insulin Homo sapiens 121-128 3065205-4 1988 A significant reduction in insulin requirements was observed in the CsA-treated children, more marked in groups II and III (p less than 0.001 vs. control group). Cyclosporine 68-71 insulin Homo sapiens 27-34 3065205-9 1988 This study demonstrates a dose-related effect of cyclosporin A (CsA) on the insulin requirements of newly diagnosed diabetic children (more frequent and prolonged remissions with the high CsA dosage). Cyclosporine 49-62 insulin Homo sapiens 76-83 3065205-9 1988 This study demonstrates a dose-related effect of cyclosporin A (CsA) on the insulin requirements of newly diagnosed diabetic children (more frequent and prolonged remissions with the high CsA dosage). Cyclosporine 64-67 insulin Homo sapiens 76-83 3065205-9 1988 This study demonstrates a dose-related effect of cyclosporin A (CsA) on the insulin requirements of newly diagnosed diabetic children (more frequent and prolonged remissions with the high CsA dosage). Cyclosporine 188-191 insulin Homo sapiens 76-83 3316278-0 1987 Effect of cyclosporin A treatment on the production of antibody in insulin-dependent (type I) diabetic patients. Cyclosporine 10-23 insulin Homo sapiens 67-74 3316278-4 1987 Conversely, cyclosporin completely suppressed the synthesis of antibodies elicited by exogenous insulin irrespective of the insulin doses received, and decreased the autoantibody production against thyroid antigens, indicating that cyclosporin has variable effects on antibody production against various antigens. Cyclosporine 12-23 insulin Homo sapiens 96-103 3554759-6 1987 Reported inductions, however, of insulin independence in patients with newly diagnosed type I diabetes using cyclosporine or other agents underscore the role of the immune system in the pathogenesis of the disease and highlight the need to develop safer, more specific immunomodulation designed to avoid complete beta-cell destruction. Cyclosporine 109-121 insulin Homo sapiens 33-40 2857945-1 1985 In 68 newly diagnosed patients with insulin-dependent diabetes mellitus (IDDM) whose treatment included cyclosporin (CyA) the prevalence and mean titre of islet cell cytoplasmic antibodies (ICA) fell faster than they did in the 56 who received only insulin. Cyclosporine 104-115 insulin Homo sapiens 36-43 3511524-9 1986 Pilot studies using cyclosporin as immunosuppressive agent in newly diagnosed type 1 diabetics have demonstrated that after discontinuation of this treatment diabetics again became insulin-dependent. Cyclosporine 20-31 insulin Homo sapiens 181-188 3038453-0 1987 Different effect of two immunomodulating agents cyclosporin A and ciamexon on the insulin metabolism of cultured mouse islets. Cyclosporine 48-61 insulin Homo sapiens 82-89 3527825-8 1986 Glucose-stimulated insulin release from perifused islets was markedly depressed in CyA-treated islets. Cyclosporine 83-86 insulin Homo sapiens 19-26 3527825-10 1986 We concluded that CyA has a direct inhibitory effect on insulin release from human pancreatic islets with a concomitant increase in the residual insulin content. Cyclosporine 18-21 insulin Homo sapiens 56-63 3527825-10 1986 We concluded that CyA has a direct inhibitory effect on insulin release from human pancreatic islets with a concomitant increase in the residual insulin content. Cyclosporine 18-21 insulin Homo sapiens 145-152 2857024-2 1985 Mean insulin dosage dropped from 46 +/- 5 U/day before cyclosporin treatment to 16 +/- 4 U/day by the 7th month. Cyclosporine 55-66 insulin Homo sapiens 5-12 31622690-11 2019 Overall, these results indicate that the IN-Z-CSA/CS0.2% nanocomposites can improve oral bioavailability of insulin and are a promising delivery system for insulin or other peptide/protein drugs. Cyclosporine 46-49 insulin Homo sapiens 108-115 3881326-0 1985 Effect of cyclosporin-A on insulin secretion in vitro. Cyclosporine 10-23 insulin Homo sapiens 27-34 6383922-3 1984 Islets cultured in the presence of the higher cyclosporin A concentration had impaired islet proinsulin biosynthesis and insulin release when challenged with high glucose concentration. Cyclosporine 46-59 insulin Homo sapiens 96-103 31622690-11 2019 Overall, these results indicate that the IN-Z-CSA/CS0.2% nanocomposites can improve oral bioavailability of insulin and are a promising delivery system for insulin or other peptide/protein drugs. Cyclosporine 46-49 insulin Homo sapiens 156-163 31490380-1 2019 RATIONALE: Immunosuppressive agents such as tacrolimus (TAC) and cyclosporin might cause glycemic disorders by suppressing insulin production. Cyclosporine 65-76 insulin Homo sapiens 123-130 27443993-7 2016 The IC50 values of cyclosporine against the mitogen-activated PBMCs in the presence of 5 or 50 muunits/mL insulin were significantly higher than those of cyclosporine without insulin (p < 0.05). Cyclosporine 19-31 insulin Homo sapiens 106-113 29380240-5 2018 Short- and long-term treatments with tacrolimus, cyclosporin A or another CNI deltamethrin (herbicide) decreased basal and insulin-dependent glucose uptake in adipocytes, without any additive effects observed when added together. Cyclosporine 49-62 insulin Homo sapiens 123-130 31402251-0 2019 Insulin Resistance in Nonobese Renal Allograft Recipients on Maintenance Doses of Cyclosporine or Tacrolimus. Cyclosporine 82-94 insulin Homo sapiens 0-7 30111091-1 2018 In this work, we use antisolvent precipitation to prepare zein/carboxymethylated short-chain amylose (CSA) complex nanoparticles for insulin encapsulation, showing that insulin-loaded zein/CSA complex nanoparticles are homogeneous, generally exhibiting sizes of <200 nm with a narrow distribution (polydispersity index < 0.100), spherical shape, and strong negative charge (-40 mV). Cyclosporine 102-105 insulin Homo sapiens 133-140 30111091-1 2018 In this work, we use antisolvent precipitation to prepare zein/carboxymethylated short-chain amylose (CSA) complex nanoparticles for insulin encapsulation, showing that insulin-loaded zein/CSA complex nanoparticles are homogeneous, generally exhibiting sizes of <200 nm with a narrow distribution (polydispersity index < 0.100), spherical shape, and strong negative charge (-40 mV). Cyclosporine 102-105 insulin Homo sapiens 169-176 30111091-1 2018 In this work, we use antisolvent precipitation to prepare zein/carboxymethylated short-chain amylose (CSA) complex nanoparticles for insulin encapsulation, showing that insulin-loaded zein/CSA complex nanoparticles are homogeneous, generally exhibiting sizes of <200 nm with a narrow distribution (polydispersity index < 0.100), spherical shape, and strong negative charge (-40 mV). Cyclosporine 189-192 insulin Homo sapiens 169-176 26735686-3 2016 The objective was to elucidate whether a conversion from tacrolimus to cyclosporine A affects fasting and/or dynamic insulin sensitivity, insulin secretion or all in HCV-positive renal transplant recipients. Cyclosporine 71-85 insulin Homo sapiens 117-124 26735686-11 2016 CONCLUSIONS: HCV-positive renal transplant recipients show significantly improved glucose-stimulated insulin sensitivity and overall glucose tolerance after conversion from tacrolimus to cyclosporine A. Cyclosporine 187-201 insulin Homo sapiens 101-108 26735686-12 2016 Considering the HCV-induced insulin resistance, HCV-positive renal transplant recipients may benefit from a cyclosporine A-based immunosuppressive regimen. Cyclosporine 108-122 insulin Homo sapiens 28-35 26849622-7 2016 The insulin-induced elevation of TRPC6 transcripts was blocked in the presence of tacrolimus, cyclosporine A, and NFAT-inhibitor (each p < 0.01 by ANOVA and Bonferroni"s multiple comparison test). Cyclosporine 94-108 insulin Homo sapiens 4-11 26849622-10 2016 Insulin increased the activity of NFATc1 in nuclear extracts (p < 0.001) whereas tacrolimus, cyclosporine A, and NFAT-inhibitor blocked that insulin effect (p < 0.001; two way ANOVA). Cyclosporine 96-110 insulin Homo sapiens 144-151 26543549-1 2015 We describe a case of type B insulin resistance syndrome associated with systemic lupus erythematosus (SLE) that was refractory to rituximab and successfully treated with a combination of oral glucocorticoids and cyclosporine. Cyclosporine 213-225 insulin Homo sapiens 29-36 26543549-3 2015 The addition of cyclosporine to oral glucocorticoid therapy resulted in remission of insulin resistance. Cyclosporine 16-28 insulin Homo sapiens 85-92 26543549-0 2015 Efficacy of oral glucocorticoid and cyclosporine in a case of rituximab-refractory type B insulin resistance syndrome. Cyclosporine 36-48 insulin Homo sapiens 90-97 26543549-4 2015 The combination of oral prednisolone and cyclosporine might be effective in treating type B insulin resistance syndrome, particularly in rituximab-resistant cases. Cyclosporine 41-53 insulin Homo sapiens 92-99